--- title: "Zepbound vs Wegovy: Which GLP-1 Is Right for You?" description: "Zepbound is tirzepatide, Wegovy is semaglutide. What the head to head trial found, how the FDA labels differ, and who each one fits. Beverly Hills clinic." canonical: https://rwacenter.com/blog/wegovy-vs-zepbound/ updated: 2026-11-05 --- - Category: weight loss program # Wegovy vs Zepbound: Which GLP-1 Is Right for You? Share on: Share on: Author: [![Picture of Biana Borchenko](https://rwacenter.com/wp-content/uploads/2024/02/BianaKrayevski-100x100.png)](https://rwacenter.com/biana-borchenko/) [Biana Borchenko](https://rwacenter.com/biana-borchenko/) - November 5, 2026 **Zepbound and Wegovy are different molecules, not two brands of the same drug.** Zepbound is tirzepatide, which activates two gut hormone receptors (GIP and GLP-1). Wegovy is semaglutide, which activates one (GLP-1). In the only head to head trial that has compared them for obesity, SURMOUNT-5, tirzepatide produced more weight loss: 20.2% of body weight at 72 weeks against 13.7% for semaglutide. That single number is what most comparisons stop at, and it is the wrong place to stop, because the two FDA labels no longer cover the same conditions. For a patient with established cardiovascular disease, Wegovy is the one with the approval. For a patient with obstructive sleep apnea, Zepbound is. This guide sets out what is actually in each drug, what the head to head trial found and what it did not test, how the labels diverge, and the honest version of the cost picture. ## Zepbound vs Wegovy at a glance | | Zepbound | Wegovy | | --- | --- | --- | | **Molecule** | Tirzepatide | Semaglutide | | **Receptors** | GIP and GLP-1 (dual) | GLP-1 only | | **Maker** | Eli Lilly | Novo Nordisk | | **Weight loss at 72 weeks (SURMOUNT-5)** | 20.2% | 13.7% | | **Waist reduction (SURMOUNT-5)** | 18.4 cm | 13.0 cm | | **Also approved for** | Moderate to severe obstructive sleep apnea in adults with obesity | Reducing major cardiovascular events; MASH with F2 to F3 fibrosis; obesity from age 12 | | **Dosing** | Weekly injection, 2.5 mg start, maintenance 5, 10 or 15 mg | Weekly injection, 0.25 mg start, 2.4 mg standard maintenance | | **Shares a molecule with** | Mounjaro | Ozempic and Rybelsus | ## What is actually in each one? The confusion is understandable, because four familiar brand names are really only two molecules. **Zepbound and Mounjaro are both tirzepatide.** **Wegovy, Ozempic and Rybelsus are all semaglutide.** What separates each pair is not the drug but the indication it was approved and priced for: Zepbound and Wegovy carry weight-related approvals, while Mounjaro and Ozempic carry type 2 diabetes approvals. The mechanical difference between the two molecules is real, though. Semaglutide is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a hormone your gut releases after eating that slows gastric emptying and signals fullness to the brain. Tirzepatide does that too, and also activates the GIP receptor, a second gut hormone pathway involved in insulin release and fat metabolism. In plain terms, tirzepatide pulls two levers where semaglutide pulls one, which is the leading explanation for the difference in the trial results below. Our guide to [semaglutide vs tirzepatide](https://rwacenter.com/blog/semaglutide-vs-tirzepatide/) covers that mechanism in more depth at the molecule level. ![Table showing that Zepbound and Mounjaro are both tirzepatide while Wegovy and Ozempic are both semaglutide, with what each is approved for.](https://rwacenter.com/wp-content/uploads/2026/11/zepbound-wegovy-brand-decoder-gh.png) Four familiar brand names, two molecules. The names track the approval, not the drug. ## Which one produces more weight loss? Tirzepatide, on the evidence available. SURMOUNT-5, published by Aronne and colleagues in the *New England Journal of Medicine* in 2025, is the only randomized head to head trial of the two drugs in adults with obesity and without type 2 diabetes. It randomized 751 participants to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg), injected weekly for 72 weeks. The results: - **Weight: 20.2% reduction with tirzepatide against 13.7% with semaglutide** (P less than 0.001). - **Waist circumference: 18.4 cm against 13.0 cm** (P less than 0.001). - Participants on tirzepatide were more likely to reach every weight threshold measured: at least 10%, 15%, 20% and 25%. - The most common adverse events in both groups were gastrointestinal, mostly mild to moderate, and concentrated during dose escalation. Three caveats belong next to those numbers, and almost no comparison article prints them. The trial was **open label** , meaning participants and investigators knew which drug was being given, which can influence reported outcomes and adherence. It was **funded by Eli Lilly** , the manufacturer of the drug that won. And the semaglutide arm was capped at 2.4 mg, which was the maximum approved maintenance dose at the time. The FDA’s own Wegovy record now also lists a higher 7.2 mg strength and an oral semaglutide tablet, neither of which existed to be tested in this trial. A head to head against the higher dose has not been published. None of that overturns the result. Tirzepatide out-performed semaglutide by a wide margin on the primary endpoint. It does mean the honest framing is “more weight loss in the one trial we have, at the doses that trial used”, not “Zepbound is simply better”. ![Chart of the SURMOUNT-5 head to head trial showing what it found and what it did not test.](https://rwacenter.com/wp-content/uploads/2026/11/surmount-5-head-to-head-gh.png) SURMOUNT-5 read honestly: what it found, and what it was not designed to answer. ## The part most comparisons skip: the two labels no longer cover the same conditions This is where the decision is actually made for a lot of patients, and it rarely appears above the fold anywhere else. **Wegovy** is approved, alongside a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with established cardiovascular disease who also have obesity or overweight. It is approved for weight reduction in adults and in adolescents from age 12. And it carries an accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver fibrosis. **Zepbound** is approved for weight reduction in adults, and to treat moderate to severe obstructive sleep apnea in adults with obesity. It does not carry a cardiovascular, adolescent or liver indication. So the question “which is better” has a different answer depending on what else is true about you. A 58 year old with a prior heart attack and a BMI of 34 is looking at a drug with a cardiovascular outcome approval on one side and no such approval on the other. A patient whose sleep study shows moderate obstructive sleep apnea is in the mirror image of that situation. A 15 year old with obesity has only one of these two available to them at all. The weight number is one input, and for these patients it is not the one that decides. ![Table comparing the FDA approved indications of Zepbound and Wegovy for cardiovascular risk, sleep apnea, liver fibrosis and adolescents.](https://rwacenter.com/wp-content/uploads/2026/11/zepbound-wegovy-label-differences-gh.png) For several groups of patients, the label decides this, not the weight loss number. ## Dosing: two different ladders Both are once-weekly subcutaneous injections, and both are titrated slowly upward rather than started at the target dose, specifically to blunt the nausea that otherwise causes people to quit in the first month. Zepbound starts at 2.5 mg weekly for four weeks. That starting dose is for initiation only and is not approved as a maintenance dose. It then moves to 5 mg, and can rise in 2.5 mg steps after at least four weeks at each level, with maintenance at 5, 10 or 15 mg. Wegovy starts at 0.25 mg weekly and steps up over roughly four months to a standard maintenance dose of 2.4 mg. Our [tirzepatide dosage chart](https://rwacenter.com/blog/tirzepatide-dosage-chart/) walks through the titration schedule and what to do about a missed dose in detail. The practical point: the published weight loss figures are from people who reached and stayed on a maintenance dose for well over a year. Someone who stalls at an early dose because of side effects, or who stops at month three, is not on the curve those numbers describe. ✓ Physician-supervised✓ Evaluation and labs first★ 5.0 on Yelp · 35+ reviews ### Not sure which GLP-1 fits your history? Generational Health runs a physician-supervised medical weight loss program in Beverly Hills using compounded semaglutide and tirzepatide. We review your history, your medications and your labs first, because these medications are not appropriate for everyone, and we escalate the dose gradually to keep side effects manageable. Semaglutide program $800 / month Tirzepatide program $925 / month Initial consultation $450 Book a weight loss consult [Weight Management →](https://rwacenter.com/weight-management/) [📞 (310) 407-0542](tel:3104070542) Three month program minimum. The initial consultation can be waived with the purchase of a package. GLP-1 medication is prescribed only by a licensed provider after a medical evaluation and is not right for everyone. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not verify the safety or effectiveness of compounded drugs. Individual results vary. ## Side effects and who should not take either The side effect profiles are broadly similar, which is expected given that both act on the GLP-1 receptor. In SURMOUNT-5 the most common adverse events in both arms were gastrointestinal, most were mild to moderate, and most occurred while the dose was being escalated rather than at maintenance. In practice that means nausea, constipation or diarrhea, abdominal discomfort and heartburn, usually worst in the days after a dose increase. Our guide to [GLP-1 side effects and how to manage them](https://rwacenter.com/blog/glp-1-side-effects/) covers what helps. Both drugs carry a boxed warning for thyroid C-cell tumors based on rodent studies, and both are **contraindicated** in the same two situations: - **A personal or family history of medullary thyroid carcinoma (MTC)** , or multiple endocrine neoplasia syndrome type 2 (MEN 2). - **A prior serious hypersensitivity reaction** to the medication or any of its components. Beyond the formal contraindications, these medications require careful review in pregnancy or when pregnancy is planned, in a history of pancreatitis, in significant gastrointestinal disease such as gastroparesis, in active gallbladder disease, and in anyone with diabetic retinopathy. Zepbound’s label also carries a limitation of use: it should not be taken alongside another tirzepatide product or any other GLP-1 receptor agonist. Baseline and follow-up [laboratory work](https://rwacenter.com/blood-testing/) is part of responsible prescribing here, not an upsell. One thing neither drug does on its own: protect muscle. A meaningful share of the weight lost on any GLP-1 is lean mass. Adequate protein and resistance training are not optional extras alongside these medications, they are what determines whether the weight you lose is the weight you wanted to lose. ## Cost, coverage, and the honest version List prices for both brands run well over a thousand dollars a month without insurance, and both manufacturers operate direct-to-patient pricing and savings programs that change frequently, so any figure printed in an article is out of date quickly. What matters more than the headline number is the coverage question, and it usually turns on indication rather than on which drug is cheaper. A plan that excludes weight loss drugs outright may still cover Wegovy for a patient with established cardiovascular disease, or Zepbound for a patient with a documented sleep apnea diagnosis, because in those cases the prescription is being written against a different approval. That is a conversation to have with your prescriber and your plan, with your diagnosis codes in front of you. ## Where compounded semaglutide and tirzepatide fit Generational Health does not dispense Zepbound or Wegovy. Our [medical weight loss program](https://rwacenter.com/weight-management/) uses compounded semaglutide and compounded tirzepatide, prescribed by a licensed provider after an in-person evaluation, with ongoing supervision, dose titration and health coaching through the program. The honest framing of what compounded means: these are the same active molecules, prepared by a compounding pharmacy rather than by Novo Nordisk or Eli Lilly. **Compounded medications are not FDA-approved, and the FDA does not verify the safety or effectiveness of compounded drugs.** The clinical trial data discussed above was generated with the branded products, so it describes the molecules rather than any particular compounded preparation. Anyone comparing options should understand that distinction before deciding, and should be wary of any provider who blurs it. If you are weighing a medication-led approach against other routes, our overview of [GLP-1 for weight loss without diabetes](https://rwacenter.com/blog/glp-1-weight-loss-without-diabetes/) and of [peptides studied for weight loss](https://rwacenter.com/blog/peptides-for-weight-loss/) set out where each one realistically sits. ## Medical Disclaimer **These statements have not been evaluated by the Food and Drug Administration.** This article is for educational purposes only and is not medical advice, and it is not intended to diagnose, treat, cure, or prevent any disease. Zepbound and Wegovy are prescription medications that must be prescribed and supervised by a licensed healthcare provider following an individual medical evaluation, and they are not appropriate for everyone. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and in anyone with a prior serious hypersensitivity reaction to the medication. Generational Health (formerly Robertson Wellness and Aesthetics), Beverly Hills, does not dispense Zepbound or Wegovy; our program uses compounded semaglutide and tirzepatide, which are not FDA-approved, and the FDA does not verify the safety or effectiveness of compounded drugs. Trial figures cited here describe group averages under study conditions. Individual results vary and are not guaranteed. Always consult a qualified healthcare provider before beginning any new treatment. ## Frequently asked questions ### Is Zepbound more effective than Wegovy? For weight loss, the evidence says yes. In SURMOUNT-5, the only randomized head to head trial, tirzepatide (Zepbound) produced a 20.2% reduction in body weight at 72 weeks against 13.7% for semaglutide (Wegovy), and participants on tirzepatide were more likely to reach every weight threshold measured. The trial was open label and funded by Eli Lilly, and it tested semaglutide at a 2.4 mg ceiling. Effectiveness for weight is also not the same as being the better choice overall, because only Wegovy carries a cardiovascular outcome approval. ### Why do people switch from Wegovy to Zepbound? Usually one of three reasons: weight loss has plateaued below the goal on a maximum Wegovy dose, side effects are intolerable on one molecule and the hope is that the other is easier, or coverage and supply changed. Switching between GLP-1 medications is a clinical decision, not a swap you make yourself. Dosing does not transfer across, you restart titration on the new drug, and the two should never be taken together. ### Is Zepbound cheaper than Wegovy? It depends entirely on coverage rather than on list price, and both manufacturers change their direct-to-patient pricing frequently. The more useful question is which one your plan will cover for your diagnosis, since a plan that excludes weight loss medication may still cover one of them written against its cardiovascular or sleep apnea indication. ### Which GLP-1 has the fastest weight loss? Among the two compared here, tirzepatide showed both greater and faster weight reduction in the head to head data. It is worth resetting expectations on the timescale, though: these are 72 week trials. Weight comes off gradually across many months, and the published averages describe people who reached and stayed on a maintenance dose, not people in their first weeks of titration. ### Is Zepbound the same as Mounjaro? Both contain tirzepatide. They are marketed under different names because they were approved for different indications, Zepbound for weight and obstructive sleep apnea, Mounjaro for type 2 diabetes. The same relationship exists between Wegovy and Ozempic, which are both semaglutide. ### Can I take Zepbound and Wegovy together? No. Zepbound’s label states that it should not be taken alongside other tirzepatide-containing products or any other GLP-1 receptor agonist, and Wegovy is a GLP-1 receptor agonist. Combining them does not double the benefit and does increase the risk of gastrointestinal adverse effects. ## Talk it through before you choose The most useful version of this decision is not made from a comparison table. It is made with your medical history, your current medications, your labs and your actual goal in front of a prescriber. Generational Health offers physician-supervised [medical weight loss](https://rwacenter.com/weight-management/) in Beverly Hills, a short distance from Cedars-Sinai, with ongoing clinical support rather than a prescription and a wave goodbye. Our [clinical team](https://rwacenter.com/about-robertson-wellness-center/meet-our-team/) will also tell you plainly when a medication is not the right move for you. [Request a consultation](https://rwacenter.com/contact/) to review your options. --- **Written and medically reviewed by Biana Borchenko, FNP-BC** , Family Nurse Practitioner, Board-Certified, with fellowship training through the American Academy of Anti-Aging Medicine (A4M), at Generational Health (formerly Robertson Wellness and Aesthetics), Beverly Hills. Biana leads the clinic’s medical weight management program, where every GLP-1 plan begins with a review of personal and family history, current medications and laboratory work, gradual dose escalation to limit gastrointestinal side effects, and attention to protein intake and resistance training to preserve muscle mass. **Sources cited in this article:** Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” *New England Journal of Medicine* , 2025;393(1):26-36. US Food and Drug Administration, ZEPBOUND (tirzepatide) prescribing information. US Food and Drug Administration, WEGOVY (semaglutide) prescribing information. US Food and Drug Administration, Drugs@FDA records for NDA 215256 (Wegovy) and NDA 217806 (Zepbound). US Food and Drug Administration, “FDA Approves First Medication for Obstructive Sleep Apnea.” [PrevPrevious](https://rwacenter.com/blog/sermorelin-dosage-side-effects/) ## Request a Consultation ## Recommended for you [![Two unbranded weekly injector pens on a warm neutral surface, introducing the Generational Health comparison of Wegovy and Zepbound.](https://rwacenter.com/wp-content/uploads/2026/11/wegovy-vs-zepbound-hero-gh-768x432.png)](https://rwacenter.com/blog/wegovy-vs-zepbound/) - [By Biana Borchenko](https://rwacenter.com/author/biana/) - November 5, 2026 ## [Wegovy vs Zepbound: Which GLP-1 Is Right for You?](https://rwacenter.com/blog/wegovy-vs-zepbound/) Zepbound is tirzepatide, Wegovy is semaglutide. The head to head trial favored tirzepatide, but the two FDA labels now cover different conditions. Here is how to choose. [read more](https://rwacenter.com/blog/wegovy-vs-zepbound/) [![An unlabeled pharmaceutical vial and syringe on a warm neutral surface, introducing the Generational Health guide to sermorelin dosing and safety.](https://rwacenter.com/wp-content/uploads/2026/11/sermorelin-dosage-hero-gh-768x432.png)](https://rwacenter.com/blog/sermorelin-dosage-side-effects/) - [By Biana Borchenko](https://rwacenter.com/author/biana/) - November 2, 2026 ## [Sermorelin Dosage and Side Effects: A Physician-Reviewed Guide](https://rwacenter.com/blog/sermorelin-dosage-side-effects/) Sermorelin has never had an FDA-approved adult dose. The only labeled doses were pediatric and diagnostic. Here is what the research actually used and what it found. [read more](https://rwacenter.com/blog/sermorelin-dosage-side-effects/) [![Vial of ARA-290 with the Generational Health mark, introducing what the clinical trials actually found.](https://rwacenter.com/wp-content/uploads/2026/10/ara-290-guide-hero-768x432.png)](https://rwacenter.com/blog/ara-290-guide/) - [By Biana Borchenko](https://rwacenter.com/author/biana/) - October 26, 2026 ## [ARA-290 (Cibinetide): Neuropathy Research, Dosing and What to Expect](https://rwacenter.com/blog/ara-290-guide/) ARA-290 has five published human trials, more than most peptides sold online. Nerve fiber density improved; pain did not separate from placebo. Here is what the research actually shows. [read more](https://rwacenter.com/blog/ara-290-guide/) [![Vial of Melanotan II with the Generational Health mark, introducing what the research actually shows.](https://rwacenter.com/wp-content/uploads/2026/10/melanotan-2-research-safety-hero-768x432.png)](https://rwacenter.com/blog/melanotan-2-research-safety/) - [By Biana Borchenko](https://rwacenter.com/author/biana/) - October 19, 2026 ## [Melanotan II: What the Research Actually Shows About Safety and Risk](https://rwacenter.com/blog/melanotan-2-research-safety/) Melanotan II has never been approved by any regulator. Its efficacy evidence is one 1996 pilot study in three men; its safety record is roughly twenty case reports. What that [read more](https://rwacenter.com/blog/melanotan-2-research-safety/) [![Vial of Selank with the Generational Health mark, introducing what the evidence amounts to.](https://rwacenter.com/wp-content/uploads/2026/10/selank-peptide-guide-hero-768x432.png)](https://rwacenter.com/blog/selank-peptide-guide/) - [By Biana Borchenko](https://rwacenter.com/author/biana/) - October 13, 2026 ## [Selank Peptide: What the Research Actually Says](https://rwacenter.com/blog/selank-peptide-guide/) Selank is a synthetic seven-amino-acid peptide developed in Russia and studied as an anxiolytic. Here is what the published research shows and what remains unproven. [read more](https://rwacenter.com/blog/selank-peptide-guide/) [![Bottle of MK-677 capsules with the Generational Health mark, introducing why MK-677 is not a peptide.](https://rwacenter.com/wp-content/uploads/2026/10/mk-677-ibutamoren-guide-hero-768x432.png)](https://rwacenter.com/blog/mk-677-ibutamoren-guide/) - [By Biana Borchenko](https://rwacenter.com/author/biana/) - October 7, 2026 ## [MK-677 (Ibutamoren): Not a Peptide, and What the Trials Actually Found](https://rwacenter.com/blog/mk-677-ibutamoren-guide/) MK-677 (ibutamoren) is not a peptide but a small synthetic molecule that activates the ghrelin receptor. Here is what the clinical trials actually found and what that means for you. [read more](https://rwacenter.com/blog/mk-677-ibutamoren-guide/)